174 related articles for article (PubMed ID: 8912865)
1. The NAD(P)H:quinone oxidoreductase locus in human colon carcinoma HCT 116 cells resistant to mitomycin C.
Hu LT; Stamberg J; Pan S
Cancer Res; 1996 Nov; 56(22):5253-9. PubMed ID: 8912865
[TBL] [Abstract][Full Text] [Related]
2. NAD(P)H:quinone oxidoreductase expression and mitomycin C resistance developed by human colon cancer HCT 116 cells.
Pan SS; Forrest GL; Akman SA; Hu LT
Cancer Res; 1995 Jan; 55(2):330-5. PubMed ID: 7812966
[TBL] [Abstract][Full Text] [Related]
3. NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity.
Traver RD; Horikoshi T; Danenberg KD; Stadlbauer TH; Danenberg PV; Ross D; Gibson NW
Cancer Res; 1992 Feb; 52(4):797-802. PubMed ID: 1737339
[TBL] [Abstract][Full Text] [Related]
4. Enzymatic and pH modulation of mitomycin C-induced DNA damage in mitomycin C-resistant HCT 116 human colon cancer cells.
Pan SS; Yu F; Hipsher C
Mol Pharmacol; 1993 Jun; 43(6):870-7. PubMed ID: 8316219
[TBL] [Abstract][Full Text] [Related]
5. Implication of alternative splicing for expression of a variant NAD(P)H:quinone oxidoreductase-1 with a single nucleotide polymorphism at 465C>T.
Pan SS; Han Y; Farabaugh P; Xia H
Pharmacogenetics; 2002 Aug; 12(6):479-88. PubMed ID: 12172217
[TBL] [Abstract][Full Text] [Related]
6. An alternatively spliced form of NQO1 (DT-diaphorase) messenger RNA lacking the putative quinone substrate binding site is present in human normal and tumor tissues.
Gasdaska PY; Fisher H; Powis G
Cancer Res; 1995 Jun; 55(12):2542-7. PubMed ID: 7780966
[TBL] [Abstract][Full Text] [Related]
7. The role of NAD(P)H:quinone oxidoreductase in mitomycin C- and porfiromycin-resistant HCT 116 human colon-cancer cells.
Pan SS; Akman SA; Forrest GL; Hipsher C; Johnson R
Cancer Chemother Pharmacol; 1992; 31(1):23-31. PubMed ID: 1458556
[TBL] [Abstract][Full Text] [Related]
8. Alternative splicing and differential expression of DT-diaphorase transcripts in human colon tumors and in peripheral mononuclear cells in response to mitomycin C treatment.
Yao KS; Godwin AK; Johnson C; O'Dwyer PJ
Cancer Res; 1996 Apr; 56(8):1731-6. PubMed ID: 8620484
[TBL] [Abstract][Full Text] [Related]
9. DT-diaphorase as a critical determinant of sensitivity to mitomycin C in human colon and gastric carcinoma cell lines.
Mikami K; Naito M; Tomida A; Yamada M; Sirakusa T; Tsuruo T
Cancer Res; 1996 Jun; 56(12):2823-6. PubMed ID: 8665520
[TBL] [Abstract][Full Text] [Related]
10. A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent.
Winski SL; Hargreaves RH; Butler J; Ross D
Clin Cancer Res; 1998 Dec; 4(12):3083-8. PubMed ID: 9865924
[TBL] [Abstract][Full Text] [Related]
11. Lack of NQO1 induction in human tumor cells is not due to changes in the promoter region of the gene.
Begleiter A; Lange L
Int J Oncol; 2002 Apr; 20(4):835-8. PubMed ID: 11894133
[TBL] [Abstract][Full Text] [Related]
12. Involvement of activator protein-1 and nuclear factor-kappaB transcription factors in the control of the DT-diaphorase expression induced by mitomycin C treatment.
Yao KS; Hageboutros A; Ford P; O'Dwyer PJ
Mol Pharmacol; 1997 Mar; 51(3):422-30. PubMed ID: 9058597
[TBL] [Abstract][Full Text] [Related]
13. NAD(P)H:quinone oxidoreductase-1-dependent and -independent cytotoxicity of potent quinone Cdc25 phosphatase inhibitors.
Han Y; Shen H; Carr BI; Wipf P; Lazo JS; Pan SS
J Pharmacol Exp Ther; 2004 Apr; 309(1):64-70. PubMed ID: 14718602
[TBL] [Abstract][Full Text] [Related]
14. Arsenite and cadmium, but not chromium, induce NAD(P)H:quinone oxidoreductase 1 through transcriptional mechanisms, in spite of post-transcriptional modifications.
Elbekai RH; El-Kadi AO
Toxicol In Vitro; 2008 Aug; 22(5):1184-90. PubMed ID: 18474416
[TBL] [Abstract][Full Text] [Related]
15. c-Maf negatively regulates ARE-mediated detoxifying enzyme genes expression and anti-oxidant induction.
Dhakshinamoorthy S; Jaiswal AK
Oncogene; 2002 Aug; 21(34):5301-12. PubMed ID: 12149651
[TBL] [Abstract][Full Text] [Related]
16. NAD(P)H:quinone oxidoreductase 1 and nrh:quinone oxidoreductase 2 activity and expression in bladder and ovarian cancer and lower NRH:quinone oxidoreductase 2 activity associated with an NQO2 exon 3 single-nucleotide polymorphism.
Jamieson D; Wilson K; Pridgeon S; Margetts JP; Edmondson RJ; Leung HY; Knox R; Boddy AV
Clin Cancer Res; 2007 Mar; 13(5):1584-90. PubMed ID: 17332305
[TBL] [Abstract][Full Text] [Related]
17. Mitomycin C resistance induced by TCF-3 overexpression in gastric cancer cell line MKN28 is associated with DT-diaphorase down-regulation.
Sagara N; Katoh M
Cancer Res; 2000 Nov; 60(21):5959-62. PubMed ID: 11085512
[TBL] [Abstract][Full Text] [Related]
18. Negative regulation of MDR1 promoter activity in MCF-7, but not in multidrug resistant MCF-7/Adr, cells by cross-coupled NF-kappa B/p65 and c-Fos transcription factors and their interaction with the CAAT region.
Ogretmen B; Safa AR
Biochemistry; 1999 Feb; 38(7):2189-99. PubMed ID: 10026303
[TBL] [Abstract][Full Text] [Related]
19. Expression of the prodrug-activating enzyme DT-diaphorase via Ad5 delivery to human colon carcinoma cells in vitro.
Misra V; Klamut HJ; Rauth AM
Cancer Gene Ther; 2002 Feb; 9(2):209-17. PubMed ID: 11857040
[TBL] [Abstract][Full Text] [Related]
20. FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations.
Fong KM; Biesterveld EJ; Virmani A; Wistuba I; Sekido Y; Bader SA; Ahmadian M; Ong ST; Rassool FV; Zimmerman PV; Giaccone G; Gazdar AF; Minna JD
Cancer Res; 1997 Jun; 57(11):2256-67. PubMed ID: 9187130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
